Product image of Mannitolo S.A.L.F. (Mannitol) supplied by GNH India

Mannitolo S.A.L.F.

Active Ingredient:
Mannitol
Origin:
EU

Mannitolo S.A.L.F. (Mannitol)

Mannitol, the active ingredient in Mannitolo S.A.L.F., is a osmotic diuretic presented as a solution for injection for intravenous use. It is employed to reduce intracranial pressure, promote diuresis in acute renal failure, and facilitate renal excretion of toxins in hospitalized patients who require rapid fluid shifts.

GNH India supplies Mannitolo S.A.L.F. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

S.A.L.F. Spa Laboratorio Farmacologico

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mannitol is an osmotic diuretic used in clinical situations that require rapid reduction of fluid volume or pressure.

  • Reduction of intracranial pressure: lowers cerebral edema and intracranial pressure in patients with head injury or neurosurgical conditions.
  • Acute renal failure: promotes diuresis to assist renal clearance in patients with oliguria.
  • Renal excretion of toxins: facilitates urinary elimination of certain nephrotoxic substances.

How It Works

  • Mannitol increases plasma osmolality by remaining largely extracellular, drawing water from intracellular and interstitial compartments into the vascular space. This osmotic shift expands intravascular volume, enhances glomerular filtration rate, and promotes renal excretion of water and solutes, thereby reducing tissue edema and intracranial pressure.

Side Effects

Mannitol may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate discomfort often reported during infusion.
  • Nausea and vomiting: gastrointestinal upset related to rapid osmotic shifts.
  • Thirst or dry mouth: sensation of increased fluid loss.
  • Electrolyte imbalance: mild hyponatremia or hypokalemia.
  • Dizziness: transient light‑headedness during or after administration.
  • Transient hypotension: due to rapid intravascular volume expansion.

Serious or Rare Side Effects

  • Pulmonary edema: fluid accumulation in the lungs, especially in patients with cardiac dysfunction.
  • Severe hypernatremia: markedly elevated serum sodium requiring urgent correction.
  • Anaphylactoid reaction: rare hypersensitivity with rash, bronchospasm, or shock.
  • Worsening renal failure: excessive diuresis leading to further kidney injury.
  • Seizures: secondary to electrolyte disturbances.
  • Cardiac arrhythmia: irregular heart rhythm linked to electrolyte shifts.

Precautions & Warnings

Mannitol should be administered with careful clinical monitoring to minimize risks.

  • Renal function: assess baseline renal status and monitor urine output.
  • Intracranial pressure: continuously evaluate neurologic status and imaging when indicated.
  • Electrolytes and osmolality: check serum electrolytes and osmolality before and during therapy.
  • Cardiovascular status: avoid rapid infusion in patients with heart failure or compromised circulation.
  • Volume status: ensure adequate intravascular volume to prevent hypotension.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Mannitol can interact with several medications, influencing fluid and electrolyte balance.

Major Interactions (Avoid)

  • Loop diuretics: may cause excessive diuresis and profound electrolyte loss.
  • Insulin: can potentiate hypoglycemia due to rapid fluid shifts.
  • Lithium: increased risk of lithium toxicity from altered renal clearance.

Moderate Interactions (Monitor Closely)

  • ACE inhibitors: may enhance renal effects and require monitoring of kidney function.
  • NSAIDs: can reduce the diuretic response and affect renal perfusion.

Frequently Asked Questions

Mannitolo S.A.L.F. is a sterile intravenous solution of mannitol, an osmotic diuretic used to lower intracranial pressure, promote diuresis in acute renal failure, and aid the renal elimination of certain toxins. It is administered in hospital settings under physician supervision.

Mannitol acts by increasing plasma osmolality, which draws water from cells and interstitial spaces into the bloodstream. This osmotic shift expands intravascular volume, raises glomerular filtration rate, and facilitates the removal of excess fluid and solutes, thereby reducing tissue edema and intracranial pressure.

The dosage of Mannitolo S.A.L.F. is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and response to therapy. Healthcare professionals calculate the appropriate infusion rate and total volume according to established clinical guidelines.

The safety of mannitol in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Mannitolo is the most commonly used osmotic diuretic for rapid reduction of intracranial pressure and promotion of diuresis. Compared with alternatives such as hypertonic saline, mannitol provides a predictable osmotic effect and is widely studied, though choice depends on the clinical scenario, patient tolerance, and physician preference.

Mannitolo S.A.L.F. must be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the solution. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required for administration.

The product is administered intravenously by slow infusion, typically through a peripheral or central line. The infusion rate and total dose are set by the prescribing clinician, who monitors vital signs, urine output, and laboratory parameters throughout the treatment.

Serious risks include pulmonary edema, severe hypernatremia, anaphylactoid reactions, worsening renal failure, seizures, and cardiac arrhythmias. Prompt recognition of these events and immediate medical intervention are essential to mitigate complications.

Mannitolo S.A.L.F. is contraindicated in patients with known hypersensitivity to mannitol, severe pulmonary congestion, uncontrolled heart failure, or active intracranial hemorrhage where increased osmotic pressure could exacerbate bleeding. Clinicians must evaluate each patient’s medical history before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.